Signatera
Personalized tumor-informed circulating tumor DNA molecular residual disease test family. Includes the FDA-authorized Signatera CDx MIBC companion-diagnostic configuration and broader laboratory-developed clinical uses that remain separately scoped.
- Developer
- Natera
- Intended use
- Mrd, Other
- Cancer scope
- Muscle-invasive bladder cancer
- Specimen
- FFPE tumor tissue, Plasma
- Molecular modality
- DNA mutation
- Current version
- Signatera CDx — MIBC ctDNA-MRD companion diagnostic
- Evidence context
- 1 structured studies · 0 indexed performance results · 3 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.